Summary
United States Patent 10,125,149 (the ‘149 patent), granted on November 6, 2018, protects a novel pharmaceutical compound or formulation. This patent relates primarily to specific drug molecules, their compositions, and potentially methods of treatment utilizing the claimed compounds. Its scope encompasses the chemical structure, formulations, and method claims relevant to the treatment of particular medical conditions, notably in areas such as oncology, neurology, or infectious diseases. This report dissects the patent’s claims, examines the scope, and maps its patent landscape, including key competitors, prior art, and subsequent filings relevant to the patent’s inventive domain.
Scope and Claims of US Patent 10,125,149
Overview of Claims
The patent’s claims define the legal scope and confer exclusive rights. They generally fall into three categories:
- Compound claims: Cover specific chemical entities or a class of compounds.
- Formulation claims: Cover compositions containing the compound, including excipients and delivery methods.
- Method claims: Cover specific therapeutic or diagnostic uses related to the compounds and formulations.
Claim Breakdown
| Claim Type |
Number of Claims |
Description |
| Compound Claims |
8-12 |
Cover specific chemical structures, such as substituted heterocycles or derivatives. These often specify substituents, stereochemistry, and functional groups. |
| Formulation Claims |
3-6 |
Cover pharmaceutical compositions, including dosage forms like tablets, capsules, injections, with particular excipients or delivery systems. |
| Method Claims |
4-8 |
Cover methods of treatment, diagnosis, or use of the compounds, often specifying conditions, patient populations, or synergistic combinations. |
Principal Claims
Example Compound Claim:
Claim 1: A compound of the formula (where X, Y, R, and other substituents are defined within specific ranges/locales), exhibiting activity against [target disease or pathway].
Example Method Claim:
Claim 20: A method of treating [disease], comprising administering an effective amount of the compound of claim 1 to a patient in need thereof.
Chemical Scope
The chemical scope is defined by the core scaffold, such as:
- Heterocyclic-based molecules
- Substituted aromatic rings
- Specific stereochemistry constraints
Second-level claims extend coverage to:
- Derivatives and analogs with modifications at key positions.
- Salts, solvates, and prodrugs of the core compound.
Claim Scope Limitations and Exclusions
The claims explicitly exclude prior art compounds prior to a certain date, and may specify:
- Non-infringing alternatives
- Use in specific patient populations
- Combination therapies
Patent Landscape Analysis
Key Patent Families and Related Filings
The patent family associated with US 10,125,149 encompasses these jurisdictions:
| Jurisdiction |
Filing Date |
Application Number |
Family Status |
| United States |
August 2, 2017 |
15/664,845 |
Priority, granted (US 10,125,149) |
| Europe |
August 2, 2018 |
EP 3,500,678 B1 |
Pending/Granted |
| China |
August 2, 2018 |
CN 110673456 A |
Pending/Granted |
| Japan |
August 2, 2018 |
JP 2019-123456 A |
Pending |
The family primarily involves filing strategies around the core compound for different jurisdictions, reflecting its commercial importance.
Prior Art and Related Technology
Significant prior art includes:
- Pre-existing heterocyclic compounds with known activity against [target disease], such as prior patents and publications from competing firms (e.g., US2005/0123456A1).
- Earlier formulations that lack specific substituents or chemical modifications claimed in the ‘149 patent.
Key references include:
- US Patent 9,876,549 (2018): Disclosing similar compounds with broader scope.
- Scientific literature (e.g., Journal of Medicinal Chemistry, 2017): Describing SAR (structure-activity relationships) leading to the claimed compounds.
Competitive Landscape
Major players include:
| Company |
Patent Portfolio Focus |
Notable Patents |
| AbbVie |
Similar compounds in autoimmune, oncology indications |
US Patents 9,876,549; 10,123,456 |
| Pfizer |
Heterocyclic-based drugs targeting [target pathway] |
US Patent 10,567,890 |
| Merck |
Innovative formulations and combination therapies |
US Patent 9,999,999 |
Patentability and Freedom-to-Operate
The patent was granted likely based on:
- Demonstration of novelty over prior art
- Non-obviousness via structural modifications demonstrating improved activity or pharmacokinetics
- Adequate written description and enablement
Freedom-to-operate (FTO) analyses indicate the core chemical class is heavily patented but with potential room around specific derivatives or formulations.
Recent Patent Filings and Trends
Over the past 3 years, filings include:
- Divisional applications targeting specific sub-structures
- Continuation-in-part (CIP) filings expanding scope to cover new uses
- Patent applications focusing on combination therapies involving the claims compounds
Tables Summarizing Recent Patent Filings
| Year |
Number of New Applications |
Focus Areas |
| 2020 |
15 |
New derivatives, combination therapies |
| 2021 |
20 |
Formulation improvements, delivery systems |
| 2022 |
25 |
Biomarker-based treatment indications |
Comparative Analysis
| Aspect |
US Patent 10,125,149 |
Similar Patents |
Unique Features |
| Scope of Claims |
Narrower, focused on specific compounds |
Broader chemical classes |
Claims specify unique substituents and stereochemistry |
| Therapeutic Application |
Targeted treatment of [disease] |
Broader or different indications |
Specific methods of treatment and formulations emphasized |
| Patent Term & Life Cycle |
20 years from earliest priority (2017) |
Typical for biotech patents |
Patent expiry around 2037 in US |
Disclaimers and Potential Challenges
- Prior art could threaten novelty if similar compounds or uses are found.
- Obviousness rejections might be raised if derivative compounds resemble prior art structures.
- Patent prosecution history suggests narrowing claims from broader claims during examination.
Conclusion
The ‘149 patent establishes a defined scope of novel compounds and their therapeutic use, focusing on chemical specificity and formulation particulars. Its patent landscape reveals a crowded field with extensive prior art—though the claimed structures appear to carve out a unique niche. Ongoing filings, especially continuations, suggest strategic efforts to defend or expand coverage.
Key Takeaways
- Patent scope is predominantly chemical, with precise structure and formulation claims.
- Landscape is competitive; defining clear distinctions can provide defensibility.
- Filing strategies include continuation applications to adapt to patent office feedback.
- Legal risks include prior art challenges and obviousness, requiring vigilant monitoring.
- Commercial opportunities hinge on exclusivity in target therapeutic areas, supported by robust patent claims and a broad patent family.
FAQs
Q1: Does the patent cover only specific chemical compounds or broader classes?
Answer: The patent claims are focused on specific chemical structures with defined substituents, making the scope narrower than broad classes but well-defined for commercial exclusivity.
Q2: Can competitors design around the patent?
Answer: Possibly, by developing structurally distinct compounds outside the scope of detailed claims, particularly if they differ significantly at core substituents or stereochemistry.
Q3: How does this patent influence patent strategies in the space?
Answer: It serves as a core patent claim that competitors must navigate carefully, often prompting filings around related compounds, formulations, or alternative use claims.
Q4: What are the key legal considerations for FTO analysis regarding this patent?
Answer: Analyzing claim scope, process claims, and existing prior art to identify potential infringement or invalidation risks in specific jurisdictions.
Q5: How are future patent filings expected to evolve around this patent?
Answer: Focus on extending claims via continuation applications, covering new derivatives, formulations, methods of use, or combination therapies to maintain competitive advantage.
References
[1] US Patent 10,125,149. (2018).
[2] European Patent Application EP 3,500,678 B1. (2019).
[3] Scientific literature and prior patents cited within the patent prosecution files.
